Shares of Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) traded down 7.5% during mid-day trading on Friday . The company traded as low as $10.08 and last traded at $10.08. 212,886 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 476,958 shares. The stock had previously closed at $10.90.
Analyst Ratings Changes
KOD has been the subject of several recent research reports. Barclays raised their price objective on Kodiak Sciences from $3.00 to $4.00 and gave the company an "underweight" rating in a research report on Friday, November 15th. Jefferies Financial Group raised shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a research report on Monday, December 9th. Finally, HC Wainwright restated a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a report on Friday, November 15th.
Get Our Latest Report on Kodiak Sciences
Kodiak Sciences Price Performance
The firm has a 50-day simple moving average of $6.50 and a 200-day simple moving average of $4.00. The firm has a market capitalization of $525.15 million, a PE ratio of -2.73 and a beta of 2.38.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of Kodiak Sciences during the 3rd quarter valued at $33,000. Meeder Asset Management Inc. purchased a new position in shares of Kodiak Sciences in the second quarter valued at about $36,000. Sanctuary Advisors LLC purchased a new position in shares of Kodiak Sciences in the second quarter valued at about $36,000. LJI Wealth Management LLC boosted its stake in shares of Kodiak Sciences by 21.3% in the third quarter. LJI Wealth Management LLC now owns 17,100 shares of the company's stock worth $45,000 after acquiring an additional 3,000 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock worth $117,000 after purchasing an additional 30,735 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Recommended Stories
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
